The FDA signed off Monday on the use of Roche’s thrombolytic drug TNKase to treat acute ischemic stroke in adult patients. According to Roche subsidiary Genentech, which announced the label expansion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback